These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38051735)

  • 1. Correction: The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    Mahumud RA; Alam K; Dunn J; Gow J
    PLoS One; 2023; 18(12):e0295688. PubMed ID: 38051735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    Mahumud RA; Alam K; Dunn J; Gow J
    PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
    Mahumud RA; Alam K; Afroz S; Ormsby GM; Dunn J; Gow J
    PLoS One; 2023; 18(11):e0294379. PubMed ID: 37943757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
    Jiang Y; Ni W; Wu J
    BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L; Joura E; Largeron N; Prager B; Uhart M
    BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
    Kiatpongsan S; Kim JJ
    PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).
    Young EJ; Tabrizi SN; Brotherton JM; Wark JD; Pyman J; Saville M; Wrede CD; Jayasinghe Y; Tan J; Gertig DM; Pitts M; Garland SM
    BMC Cancer; 2013 Jun; 13():296. PubMed ID: 23777549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.
    Kulasingam S; Connelly L; Conway E; Hocking JS; Myers E; Regan DG; Roder D; Ross J; Wain G
    Sex Health; 2007 Sep; 4(3):165-75. PubMed ID: 17931529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
    Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
    BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.
    Mennini FS; Bonanni P; Bianic F; de Waure C; Baio G; Plazzotta G; Uhart M; Rinaldi A; Largeron N
    Cost Eff Resour Alloc; 2017; 15():11. PubMed ID: 28701899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from australia.
    The
    PLoS One; 2015; 10(2):e0117962. PubMed ID: 25658818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review.
    Mahumud RA; Alam K; Keramat SA; Ormsby GM; Dunn J; Gow J
    PLoS One; 2020; 15(6):e0233499. PubMed ID: 32484811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
    BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
    Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
    Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community.
    Egbon M; Ojo T; Aliyu A; Bagudu ZS
    BMC Public Health; 2022 Aug; 22(1):1611. PubMed ID: 36002832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.